Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
BTC
Name:
betacellulin
Location:
04q13.3
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT00873132 | BTC Neuropsychological Database | View | |
| NCT01180153 | Study of S-1 Oxaliplatin SOX for Biliary Tract Cancer BTC Ampullary Adenocarcinoma | View | |
| NCT01508221 | Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis | View | |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer BTC | View | |
| NCT02349724 | A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | View | |
| NCT04896931 | New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma PERSUASION- a Permanent Platform Including All Kind of Biliary Tract Cancers BTC | View | |
| NCT02821754 | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma HCC or Biliary Tract Carcinomas BTC | View | |
| NCT03704480 | Durvalumab Tremelimumab Paclitaxel in Advanced BTC After Platinum Chemotherapy | View | |
| NCT03937830 | Combined Treatment of Durvalumab Bevacizumab Tremelimumab and Transarterial Chemoembolization TACE in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | View | |
| NCT05271994 | Fesibility of EUS-guided Gallbladder Drainage With a New-type of Electrocautery LAMS in the Treatment of Malignant Distal Biliary Obstruction | View | |
| NCT04318834 | Molecular Profiling of Advanced Biliary Tract Cancers | View | |
| NCT04550624 | Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma | View | |
| NCT04566133 | Combination of Trametinib MEK Inhibitor and Hydroxychloroquine HCQ Autophagy Inhibitor in Patients With KRAS Mutation Refractory Bile Tract Carcinoma BTC | View | |
| NCT04723199 | Feasibility of EUS-guided Biliary Drainage With LAMS for the Treatmentof Patients With Distal Malignant Biliary Obstruction | View | |
| NCT04727996 | Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer | View | |
| NCT04856761 | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | View | |
| NCT04298021 | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | View | |
| NCT05749900 | First-line Trastuzumab Gemcitabine Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer a Multicenter Open-label Single-arm Phase IbII Trial HERBOT | View | |
| NCT05768815 | Optimizing Mental Health for Infants Exposed to Early Adversity A Comparison of Breaking the Cycle and Maxxine Wright | View | |
| NCT05942807 | Observational Monocentric Study on Biliary Tract Cancer BABEL | View | |
| NCT06084481 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous IV ABBV-400 | View | |
| NCT03937895 | Allogeneic NK Cell SMT-NK in Combination With Pembrolizumab in Advanced Biliary Tract Cancer | View | |
| NCT01169415 | Effects of Steroid Tapering on Functional Capacity and Neurocognition | View | |
| NCT04466891 | A Study of ZW25 Zanidatamab in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | View | |
| NCT03609554 | Improvements in Adolescents With Back Pain After Pilates | View | |
| NCT00832637 | Gemcitabine Oxaliplatin Tarceva or Cisplatin in HCC Biliary Tree Cancers | View | |
| NCT01127555 | Salvage mFOLFOX in BTC After Failure of Gemcitabine | View | |
| NCT01171755 | Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer | View | |
| NCT01191346 | Radiation Planning Study for High Grade Brain Tumors | View | |
| NCT01216345 | Cetuximab Gemox in Biliary Tract Cancer | View | |
| NCT01234051 | Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer | View | |
| NCT02170090 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer | View | |
| NCT01267344 | A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC | View | |
| NCT04784520 | A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer | View | |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma NSCLC Transitional Cell Carcinoma of the Urothelium or Biliary Tract Cancer | View | |
| NCT01436019 | Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis | View | |
| NCT04866836 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors | View | |
| NCT04871321 | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer | View | |
| NCT03110510 | FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer BTC Patients Who Were Failed After Gemcitabine Containing Chemotherapy A Phase II Single Arm Prospective Study | View | |
| NCT03111732 | Pembrolizumab a Monoclonal Antibody Against PD-1 in Combination With Capecitabine and Oxaliplatin CAPOX in People With Advanced Biliary Tract Carcinoma BTC | View | |
| NCT02992340 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | View | |
| NCT03008096 | Laparoscopic Sleeve Gastrectomy as Bridge-to-Candidacy for Obese Left-Ventricular Assist Device Patients | View | |
| NCT01811277 | SOX Sequential S-1 in Advanced Biliary Tract CarcinomaBTCand Pancreatic Cancer | View | |
| NCT03311789 | Study of PD-1 Inhibitor in Combination With GemcitabineCisplatin for Advancer BTCs | View | |
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | View | |
| NCT05239169 | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | View | |
| NCT05237193 | A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up | View | |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 Tinengotinib as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | View | |
| NCT05327582 | An Open-label Phase III Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | View | |
| NCT03260712 | Pembrolizumab in Biliary Tract Cancer | View | |
| NCT03419247 | Molecular Profiling of Advanced Biliary Tract Cancers | View | |
| NCT05487443 | The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies | View | |
| NCT05509478 | Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for UnresectableAdvanced Biliary Tract Carcinoma | View | |
| NCT03673072 | Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC | View | |
| NCT03684733 | Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer | View | |
| NCT02386397 | Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer | View | |
| NCT03531320 | Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase | View | |
| NCT02549937 | A Multi-Center Open-Label Study of Surufatinib HMPL-012 in Patients With Advanced Solid Tumors | View | |
| NCT01821248 | A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer BTC With Node Metastasis | View | |
| NCT05742750 | A Phase IbII Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer | View | |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | View | |
| NCT02725996 | By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy | View | |
| NCT02734524 | A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer | View | |
| NCT02773459 | MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer | View | |
| NCT03790111 | A Safety and Efficacy Study of XERMELO First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer | View | |
| NCT02866383 | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | View | |
| NCT02937103 | A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | View | |
| NCT02935153 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | View | |
| NCT02943031 | The Effect of Individualized Precision Therapy Programs in Patients With BTC | View | |
| NCT02958410 | A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies | View | |
| NCT02958397 | A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies | View | |
| NCT02958384 | A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies | View | |
| NCT03110484 | Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer BTC Who Failed Gemcitabine Containing Chemotherapy A Phase II Single Arm Prospective Study | View | |
| NCT03092895 | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | View | |
| NCT03144856 | Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers | View | |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors BLOCKED | View | |
| NCT05291052 | Tisleizumab Combined With Lenvatinib and XELOX Regimen Oxaliplatin Combined With Capecitabine in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors | View | |
| NCT06178445 | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer | View | |
| NCT04796454 | Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer | View | |
| NCT04641871 | Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies | View | |
| NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | View | |
| NCT03613168 | Trastuzumab in HER2-positive Biliary Tract Cancer | View | |
| NCT03639935 | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | View | |
| NCT04720131 | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer | View | |
| NCT06330064 | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan I-DXd In Subjects With Recurrent Or Metastatic Solid Tumors IDeate-PanTumor02 | View | |
| NCT03768531 | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | View | |
| NCT03779035 | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection | View | |
| NCT03778593 | FOLFIRINOX for 2nd-line Treatment of BTC | View | |
| NCT04924062 | Pembrolizumab MK-3475 Plus GemcitabineCisplatin Versus Placebo Plus GemcitabineCisplatin for First-Line Advanced andor Unresectable Biliary Tract Carcinoma BTC MK-3475-966KEYNOTE-966-China Extension Study | View | |
| NCT03797326 | Efficacy and Safety of Pembrolizumab MK-3475 Plus Lenvatinib E7080MK-7902 in Previously Treated Participants With Select Solid Tumors MK-7902-005E7080-G000-224LEAP-005 | View | |
| NCT03801083 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | View | |
| NCT03818997 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | View | |
| NCT03833661 | M7824 Monotherapy in Locally Advanced or Metastatic Second Line 2L Biliary Tract Cancer Cholangiocarcinoma and Gallbladder Cancer | View | |
| NCT06430827 | Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma | View | |
| NCT03875235 | Durvalumab or Placebo in Combination With GemcitabineCisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 | View | |
| NCT06490107 | Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC | View | |
| NCT03943043 | Gemcitabine Oxaliplatin Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | View | |
| NCT06465563 | Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer | View | |
| NCT04003896 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | View | |
| NCT04003636 | Pembrolizumab MK-3475 Plus GemcitabineCisplatin Versus Placebo Plus GemcitabineCisplatin for First-Line Advanced andor Unresectable Biliary Tract Carcinoma BTC MK-3475-966KEYNOTE-966 | View | |
| NCT05023109 | GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC | View | |
| NCT04057365 | Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer BTC | View | |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa M7824 in Participants With 1L BTC | View | |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | View | |
| NCT05410197 | Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line TreatmentENLIGHTEN | View | |
| NCT06569225 | GemcitabineCisplatinNab-Paclitaxel and Rilvegostomig in Resectable iCCA | View | |
| NCT04186156 | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer | View | |
| NCT05429697 | Study of SMT-NK Inj Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer | View | |
| NCT04217954 | HAIC With Oxaliplatin 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC | View | |
| NCT06564623 | Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers BTC | View | |
| NCT05653180 | IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer | View | |
| NCT05667350 | AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer ASCEND-BTC | View | |
| NCT04298008 | AZD6738 Plus Durvalumab in Biliary Tract Cancer | View | |
| NCT04329429 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | View | |
| NCT05781074 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer CASTLE-08 | View | |
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | View | |
| NCT04578444 | An Expanded Access Treatment Protocol of Zanidatamab ZW25 in Patients With HER2-Positive Advanced Biliary Tract Cancer | View | |
| NCT05812430 | Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer | View | |
| NCT04677504 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated Advanced Biliary Tract Cancer | View | |
| NCT04704154 | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | View | |
| NCT04976634 | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors MK-6482-016 | View | |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | View | |
| NCT05036486 | The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer | View | |
| NCT05041972 | ARX788 in Selected HER2-mutated or HER2-amplifiedOverexpressed Solid Tumors ACE-Pan Tumor-02 | View | |
| NCT03046862 | DurvalumabMEDI4736Tremelimumab in Combination With GemcitabineCisplatin in Chemotherapy-naïve Biliary Tract Cancer | View | |
| NCT05064852 | A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma | View | |
| NCT05094336 | A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors | View | |
| NCT06607276 | Adebrelimab Combined With Capecitabine for Adjuvant Therapy in Cholangiocarcinoma With High-risk Recurrence Post-surgery | View | |
| NCT05156788 | TislelizumabAnti PD-1 Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable Locally Advanced Biliary Tract Cancer | View | |
| NCT06181032 | A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies | View | |
| NCT05190575 | TST001 in Patients With CLDN182 Positive Previously Treated Advanced Biliary Tract Cancer | View | |
| NCT06320301 | Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers BTC | View | |
| NCT05254847 | Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC | View | |
| NCT06591520 | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | View | |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | View | |
| NCT06648057 | Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab | View | |
| NCT05350943 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | View | |
| NCT06611345 | A Study of Tumor-Treating Fields in Combination With Durvalumab and GemcitabineCisplatin in Biliary Tract Cancers | View | |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | View | |
| NCT01943864 | A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers | View | |
| NCT01949870 | Selumetinib AZD6244 ARRY-142886 J-BTC Phase 1 Study | View | |
| NCT05640791 | Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer | View | |
| NCT01980186 | Transcranial Ultrasonography Using Linear 2D Imaging of the Brain | View | |
| NCT06622057 | D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer | View | |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | View | |
| NCT05823987 | Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer OPTIONS-05 | View | |
| NCT05822453 | Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | View | |
| NCT05835778 | Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance PMS Study - CEISCEI | View | |
| NCT05849480 | A Study of CDX-1140 a CD40 Agonist in Combination With Capecitabine and Oxaliplatin CAPOX and Keytruda in Subjects With Biliary Tract Carcinoma BTC | View | |
| NCT05924880 | A Phase 3b Open-label Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers BTC | View | |
| NCT06653127 | Circulating Tumor Mitochondrial DNA ct-mtDNA As a Biomarker for Resected Biliary Tract Cancer Recurrence Surveillance | View | |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | View | |
| NCT05994001 | Candonilimab in Combination With LM-302 for Claudin 182 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1PD-L1 Antibody | View | |
| NCT06001658 | Perioperative Gemcitabine Cisplatin and Pembrolizumab in Potentially Resectable Biliary Tract Cancers | View | |
| NCT06013943 | Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC | View | |
| NCT06024174 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine KRAS G12C-Mutant Solid Tumors | View | |
| NCT06037655 | Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC | View | |
| NCT06037980 | CisPlatin plUs Gemcitabine and Nabpaclitaxel GAP as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers BTC at High Risk for Recurrence | View | |
| NCT06048133 | Study of Gemcitabine Cisplatin AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers QUIC | View | |
| NCT06062485 | Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma | View | |
| NCT06074029 | Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | View | |
| NCT06109779 | Rilvegostomig Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection ARTEMIDE-Biliary01 | View | |
| NCT06282120 | Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FULV Immunotherapy in First-line Gemsitabine Immunoprogressive Patients With Metastatic Biliary Tract Cancer | View | |
| NCT06413745 | Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer | View | |
| NCT06502080 | Consolidative Radiotherapy CSRT in Patients With OligometastaticLocally Advanced Unresectable Bilary Tract Cancer BTC | View | |
| NCT02710149 | A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies | View | |
| NCT01525459 | Gene Expression Immunological Status and Metabolome in Glioma Patients | View | |
| NCT00504192 | A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | View | |
| NCT02349698 | A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | View | |
| NCT02579616 | Study of Lenvatinib E7080 in Unresectable Biliary Tract Cancer BTC Who Failed Gemcitabine-based Combination Chemotherapy | View | |
| NCT02954445 | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | View | |
| NCT03478488 | Programmed Death Ligand PD-L1 Combined With Chemotherapy for Patients With BTC | View | |
| NCT03486678 | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC | View | |
| NCT03873532 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | View | |
| NCT03929666 | A Safety and Efficacy Study of ZW25 Zanidatamab Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers Including Gastroesophageal Adenocarcinoma Biliary Tract Cancer and Colorectal Cancer | View | |
| NCT04004234 | A Phase III Study of the Pan-immunotherapy in Patients With Local AdvancedMetastatic BTC | View |